Exosomes in Hepatocyte Repair and Liver Regeneration: Biological Mechanisms, Autologous Strategies, and Translational Evidence

Abstract

Background: Exosomes and related small extracellular vesicles (EVs) participate in intercellular signalling during liver injury and regeneration. Selected EV preparations can influence hepatocyte survival and proliferation, oxidative and mitochondrial stress, inflammatory responses, and hepatic stellate-cell activation. Autologous blood-derived EV strategies are attractive because collection is patient-specific, but disease state and pre-analytical handling may alter vesicle composition and biological activity.

Objective: To critically synthesise evidence on exosome- and EV-mediated hepatocyte repair and liver regeneration, with particular emphasis on autologous approaches and the translational requirements of the Biotex Autologous Exosome Isolation Kit (manufacturer designation), a developed point-of-care blood-derived EV-enrichment system.

Methods: A structured narrative review was conducted using PubMed/MEDLINE as the principal biomedical index, with cross-checking against publisher and version-of-record pages. Peer-reviewed literature available through August 2026 was considered. Evidence was weighted toward human studies, then large-animal and rodent in vivo studies, primary-cell or organoid experiments, and mechanistic cell studies. Preprints, promotional webpages, unverified testimonials, and unsupported commercial claims were excluded from the evidentiary core. Vesicle terminology was interpreted in accordance with MISEV2023.

Results: Direct mechanistic evidence shows that hepatocyte-derived exosomes can promote hepatocyte proliferation through neutral ceramidase/sphingosine kinase 2/sphingosine-1-phosphate signalling. Hepatic-progenitor- and mesenchymal-stromal-cell-derived EVs have demonstrated regenerative, antioxidant, anti-apoptotic, immunomodulatory, and antifibrotic effects in experimental liver models through cargo including miR-183-5p and GPX1 and through pathways involving Akt/GSK3beta/beta-catenin, TXNIP/NLRP3, SLC7A11/GPX4, TGF-beta/SMAD, Wnt/beta-catenin, and Hedgehog/SMO. Circulating EV profiles also change during human liver regeneration, but human evidence remains predominantly observational. Autologous serum EVs show source- and disease-state-dependent biological activity, and no controlled human study was identified in which intravenously administered autologous blood-derived EVs regenerated damaged liver tissue.

Conclusion: Exosome- and EV-mediated liver repair is supported by substantial mechanistic and preclinical evidence, whereas therapeutic efficacy of autologous blood-derived EV preparations in human liver disease remains unestablished. Translation therefore depends on product-specific demonstration of EV identity, contaminant depletion, reproducible liver-relevant potency, haemocompatibility and safety, biodistribution, pharmacokinetics, and controlled clinical efficacy.